Predicting Early and Late Mortality After Transcatheter Aortic Valve Replacement
- PMID: 27443429
- DOI: 10.1016/j.jacc.2016.04.057
Predicting Early and Late Mortality After Transcatheter Aortic Valve Replacement
Abstract
Background: Few studies have examined the impact of novel indices of comorbidity, frailty, and disability on outcomes after transcatheter aortic valve replacement (TAVR).
Objectives: This study analyzed patients from the Medtronic CoreValve U.S. Pivotal Trial program to develop a simple scoring system that incorporates standard and novel predictor variables.
Methods: A multidisciplinary heart team used objective criteria, such as The Society of Thoracic Surgeons Predicted Risk of Mortality (STS PROM), and subjective criteria to assess patients' eligibility for TAVR. The analysis included 3,687 patients randomly divided (2:1) into a derivation cohort (n = 2,482) and a validation cohort (n = 1,205). The study evaluated predictors of all-cause death, which were used to calculate a risk score for each patient.
Results: The overall mortality rate was 5.8% at 30 days and 22.8% at 1 year. Home oxygen use, assisted living, albumin levels <3.3 g/dl, and age >85 years predicted death at 30 days. Home oxygen use, albumin levels <3.3 g/dl, falls in the past 6 months, STS PROM score >7%, and severe (≥5) Charlson comorbidity score predicted death at 1 year. A simple scoring system created on the basis of these multivariable predictors effectively stratified risk at 30 days and 1 year into low-risk, moderate-risk, and high-risk subsets. This score showed a 3-fold difference in mortality rates for the low-risk and high-risk subsets at 30 days (3.6% and 10.9%, respectively) and 1 year (12.3% and 36.6%, respectively). The 1-year mortality model was more stable than the 30-day model (C-statistics: 0.79 vs. 0.75).
Conclusions: A simple score dominated by novel predictors of outcome effectively stratified early and late mortality rates in extreme-risk and high-risk patients and may assist in selecting appropriate candidates for TAVR. (Safety and Efficacy Study of the Medtronic CoreValve System in the Treatment of Symptomatic Severe Aortic Stenosis in High Risk and Very High Risk Subjects Who Need Aortic Valve Replacement; NCT01240902).
Keywords: aortic stenosis; predictors of mortality; transcatheter aortic valve implantation.
Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Comment in
-
TAVR Risk Assessment: Does the Eyeball Test Have 20/20 Vision, or Can We Do Better?J Am Coll Cardiol. 2016 Jul 26;68(4):353-5. doi: 10.1016/j.jacc.2016.05.030. J Am Coll Cardiol. 2016. PMID: 27443430 No abstract available.
-
A Better Scoring System for Mortality After Transcatheter Aortic Valve Replacement.J Am Coll Cardiol. 2017 Jan 31;69(4):468-469. doi: 10.1016/j.jacc.2016.08.086. J Am Coll Cardiol. 2017. PMID: 28126166 No abstract available.
-
Risk Models for Transcatheter Aortic Valve Replacement.J Am Coll Cardiol. 2017 Jan 31;69(4):468. doi: 10.1016/j.jacc.2016.08.088. J Am Coll Cardiol. 2017. PMID: 28126167 No abstract available.
-
Comprehensive Geriatric Assessment and Transcatheter Aortic Valve Replacement.J Am Coll Cardiol. 2017 Jan 31;69(4):469-470. doi: 10.1016/j.jacc.2016.08.087. J Am Coll Cardiol. 2017. PMID: 28126168 No abstract available.
-
Reply: TAVR: Risk Models, Mortality Scoring, and Geriatric Assessment.J Am Coll Cardiol. 2017 Jan 31;69(4):470. doi: 10.1016/j.jacc.2016.10.070. J Am Coll Cardiol. 2017. PMID: 28126169 No abstract available.
Publication types
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous